Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The share is getting closer to its long-term support in weekly data, at JPY 1435, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • Below the resistance at 1698 JPY, the stock shows a negative configuration when looking looking at the weekly chart.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTELLAS PHARMA INC.-19.22%26 686
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357
NOVO NORDISK A/S8.79%158 090
BRISTOL-MYERS SQUIBB COMPAN..-3.75%140 511
ASTRAZENECA PLC4.34%138 967
AMGEN INC.-5.87%131 896
ELI LILLY AND COMPANY9.65%131 599
SANOFI-7.35%127 565
GLAXOSMITHKLINE PLC-21.66%92 552
CHUGAI PHARMACEUTICAL CO., ..47.95%77 766
JIANGSU HENGRUI MEDICINE CO..23.39%70 476
More Results
Financials
Sales 2021 1 272 B 12 241 M 12 241 M
Net income 2021 190 B 1 825 M 1 825 M
Net cash 2021 444 B 4 274 M 4 274 M
P/E ratio 2021 14,7x
Yield 2021 2,79%
Capitalization 2 806 B 27 024 M 27 008 M
EV / Sales 2021 1,86x
EV / Sales 2022 1,68x
Nbr of Employees 15 883
Free-Float 99,2%
Upcoming event on ASTELLAS PHARMA INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes